Last updated: February 14, 2026
Product Profile and Therapeutic Indication
The drug identified by NDC 72205-0009 is specified as a medication primarily used in oncology. It is marketed under the brand name Axicabtagene ciloleucel, a CAR-T cell therapy targeting large B-cell lymphoma. It is approved for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. The product is manufactured by Kite Pharma, a Gilead Sciences subsidiary.
Market Size and Segments
Target Population:
The eligible patient population includes adults with relapsed/refractory large B-cell lymphoma. Approximately 7,000-8,000 new cases are diagnosed annually in the U.S., with about 20-30% becoming refractory or relapsed after initial therapy [1].
Market Penetration:
Currently, the market penetration approaches 25-30% among eligible patients, driven by the adoption rate of CAR-T therapies, which has increased as hospitals develop infrastructure for cell therapy delivery.
Key Competitors:
Other CAR-T therapies approved for this indication include:
- Kymriah (Tisagenlecleucel) by Novartis
- Breyanzi (Lisocabtagene maraleucel) by Bristol-Myers Squibb
The competitive landscape influences market share and pricing strategies.
Pricing Overview
Initial Pricing:
The Wholesale Acquisition Cost (WAC) for NDC 72205-0009 was approximately $399,000 per dose at approval in 2021. Actual transaction prices are lower due to negotiations, rebates, and discounts.
Pricing Trends:
Prices have remained relatively stable, with minor adjustments for inflation and reimbursement policies. The CMS and private payers’ discounts typically reduce net prices by 20-30%.
Market Dynamics and Pricing Drivers
-
Reimbursement Policies:
Insurance coverage for CAR-T therapies predominantly involves value-based agreements and outcomes-based reimbursements.
-
Manufacturing and Administration Costs:
High manufacturing costs recurrently influence pricing, especially for autologous therapies like CAR-Ts.
-
Regulatory and Policy Changes:
Pricing and reimbursement are sensitive to FDA approvals and regulatory updates. The recent approval for earlier line indications could expand market size, potentially impacting prices through increased competition and volume.
Projected Price Adjustments (Next 2-5 Years):
Avoiding significant price reductions, projections suggest a slight decrease of 5-10% in net prices due to increased competition and cost efficiencies. Any uptake in expanded indications could stabilize or slightly increase net revenue due to higher volumes.
Revenue and Market Forecasts
-
Current Market Value:
Estimations indicate approximately $1.2 billion in U.S. sales for all CAR-T therapies targeting large B-cell lymphoma (2022).
-
For NDC 72205-0009:
Given the market share (~30%), current revenues approximate $360 million annually.
-
Future Growth:
An annual compound growth rate (CAGR) of 10-15% is predicted for CAR-T therapy sales over the next 3-5 years, driven by expanded indications and increased adoption rates.
Pricing Projections Summary Table
| Year |
Estimated Price per Dose |
Volume Estimates |
Estimated Revenue |
| 2023 |
$399,000 |
8,000 doses |
$3.2 billion (for all CAR-Ts) |
| 2024 |
$378,000 |
8,500 doses |
$3.21 billion |
| 2025 |
$360,000 |
9,500 doses |
$3.24 billion |
(These are approximations based on current trends and market intelligence; actual figures depend on negotiations, policy shifts, and market adoption.)
Key Takeaways
- NDC 72205-0009 is a CAR-T therapy with a price point around $399,000 per dose.
- The market for large B-cell lymphoma CAR-T therapy exceeds $1 billion annually in the U.S.
- Volume growth and expanded indications are primary factors influencing revenue projections.
- Prices are expected to decline modestly over the next two years due to increased competition and policy adjustments but could stabilize with expanded use.
- Reimbursement strategies, especially value-based arrangements, remain critical for revenue realization.
FAQs
1. How does the pricing of NDC 72205-0009 compare to competitors?
It is roughly on par with other CAR-T therapies, such as Kymriah and Breyanzi, with initial WACs between $399,000 and $475,000 per dose.
2. What factors influence the net selling price?
Negotiated rebates, discounts, payer contracts, and value-based agreements. These typically reduce the list price by 20-30%.
3. What is the potential impact of expanded indications?
Broader approval could increase patient volume, potentially offsetting slight price reductions and leading to higher aggregate revenue.
4. How does reimbursement policy affect pricing?
Value-based reimbursement models pressure manufacturers to demonstrate clinical outcomes to maintain favorable pricing.
5. What are the key risks to revenue forecasts?
Emergence of biosimilars or other innovative therapies, regulatory changes, and shifts in reimbursement policies.
Citations
[1] American Cancer Society. "Cancer Facts & Figures 2022."
